Dana W. Spigelman
Dana Spigelman represents private equity funds and their portfolio companies, as well as emerging companies, in mergers, acquisitions, equity investments, fund formation, capital raising, buyout transactions, dispositions, and other strategic transactions and general corporate matters. He works with a wide range of clients, but has particular experience in the technology, healthcare, life sciences, and consumer products industries.
Representative Engagements
- Summit Partners in a growth funding round in CoderPad.
- Representation of Perceptive Xontogeny Ventures in early-stage investments in drug development companies, such as AsclepiX Therapeutics and CereVasc.
- New Heritage Capital in its platform investment in DeWinter Group.
- New Heritage Capital in its investment in Welcome Dairy Holdings.
Education & Credentials
- Boston University School of Law
- JD, 2017, magna cum laude
- Syracuse University
- BA, 2012
Admissions
Massachusetts
Focus Area
Dana's Insights
Announcements 12.12.2024
Becklar, a BV Investment Partners Portfolio Company, Announces Investment from Graham Partners
Choate represented BV Investment Partners and its portfolio company, Becklar, in Becklar's investment from Graham Partners.
Announcements 07.18.2024
Spectrum Equity Makes Strategic Investment in Varicent
Choate represented Spectrum Equity in its strategic investment in Varicent, the industry leader in sales performance management (SPM) software.
Announcements 05.09.2024
Riverside Partners Invests in Net32
Choate represented Riverside Partners in its investment in Net32, a North Carolina-based online marketplace for purchasing dental supplies.